Biotech RadarJobs updated

COMPANY

Creative Medical Technology Holdings

HQ: Phoenix, AZ source · creativemedicaltechnology.com ↗

Clinical Phase 2

Keywords: immunology regenerative medicine Chronic Low-back Pain Degenerative Disc Disease Burn Pit Exposure Airborne Hazard Exposure Veteran Health Deployment-Related Toxic Exposure Biomarkers Immune Dysfunction Respiratory Symptoms Type 1 Diabetes Type 1 Diabetes Mellitus Chronic Back Pain Degenerative Disc Disease Lumbar CELZ-201-DDT CELZ-201 Administration

Location: Phoenix, AZ · source · Oct 14, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

  1. Trial start —: Project PHOENIX: Molecular Signatures of Burn Pit Exposure source ↗
  2. Trial start Phase 1/Phase 2: Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain source ↗
  3. Trial start Phase 1/Phase 2: Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT06053242Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back PainPhase 1/Phase 2Active, not recruitingMay 21, 2024Jan 20, 2027 (estimated)
NCT07562243Project PHOENIX: Molecular Signatures of Burn Pit ExposureNot listedNot yet recruitingMay 1, 2026May 1, 2029 (estimated)
NCT05626712Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 DiabetesPhase 1/Phase 2RecruitingApr 7, 2023Jan 31, 2027 (estimated)
NCT07137559CELZ-201-DDT for the Treatment of Chronic Lower Back PainNot listedAvailableNot listedNot listed
Feedback